News of Note—Sanofi, Dynavax and more


Here is some other vaccine news of note for the week:

> The FDA approved an expanded use for Sanofi's Tdap vaccine Adacel to allow for repeat vaccinations. Release

> Dynavax predicts an "inflection point" in sales for its Heplisav-B vaccine and that the vaccine will be profitable by the end of 2019. Presentation


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> The Coalition for Epidemic Preparedness Innovations (CEPI) tapped the University of Queensland in a deal worth up to $10.6 million to develop a “molecular clamp” vaccine platform, which enables rapid vaccine production against multiple viral pathogens. Release

> Univercells launched its low-cost vaccine production system, NevoLine, triggering a $4 million grant extension from the Bill & Melinda Gates Foundation to scale up the platform. Release


Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.